The MATTER Health Podcast cover image

Tales from the Trenches™ with Sheila Mikhail, Co-founder and CEO of AskBio

The MATTER Health Podcast

00:00

Gene Therapy - One Time Treatments

In the early days of gene therapy, there was a concern that payers and insurance companies wouldn't pay high enough of a price to offset the revenue streams from a more recurring treatment. The drug for SMA by VEX's now Novartis got approved. These drugs have high prices associated with them, but it's necessary because without those higher prices, I don't think you would see as much money and innovation in the sector.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app